Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure

AJP Lung Cellular and Molecular Physiology (Impact Factor: 4.04). 01/2012; 302:L736-L745.

ABSTRACT Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling
following repeated allergen exposure. Am J Physiol Lung Cell Mol
Physiol 302: L736–L745, 2012. First published January 27, 2012;
doi:10.1152/ajplung.00050.2011.—Sphingosine-1-phosphate (S1P) is
an immunomodulatory lipid mediator that plays an important role in
lymphocyte trafficking. Elevated levels of S1P are found in bronchoalveolar
lavage (BAL) fluid of patients with asthma; however, its
role in disease is not known. FTY720, a synthetic analog of S1P, has
been shown to abrogate allergic inflammation and airway hyperresponsiveness
following acute allergen challenge. However, its effects
on asthmatic airway remodeling induced by repeated allergen exposure
are unknown. Ovalbumin (OVA)-sensitized rats were challenged
on days 14, 19, and 24 after sensitization. FTY720 or vehicle (PBS)
therapy was administered 1 h prior to each challenge. BAL fluid and
quantitative histological analysis were performed 48 h after the last
challenge. FTY720 inhibited OVA-induced features of airway remodeling
including increased airway smooth muscle mass and bronchial
neovascularization, without affecting lymphocyte numbers in secondary
lymphoid organs. Furthermore, CD3� cells adjacent to airway
smooth muscle bundles were increased in OVA-challenged rats but
the increase was inhibited by FTY720. There was an expansion of
bronchus-associated lymphoid tissue following FTY720 treatment of
OVA-challenged animals. Real-time quantitative PCR revealed that
Th2-associated transcription factors were inhibited following FTY720
therapy. Airway remodeling is a cardinal feature of severe asthma.
These results demonstrate that allergen-driven airway remodeling can
be inhibited by FTY720, offering potential new therapies for the
treatment of severe asthma.


Available from: Sana Siddiqui, May 29, 2015
  • The FASEB Journal 06/2001; 15(7):1212-4. · 5.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The enzyme sphingosine kinase (SK) catalyzes the formation of sphingosine 1-phosphate (S1P), a bioactive lipid that acts extracellularly on G protein-coupled receptors of the S1P(1)/EDG-1 subfamily. Although S1P is formed in the cytosol of various cells, S1P release is not understood and is controversial because this lipid mediator is also regarded as a second messenger. In this report, we describe the existence of an extracellular S1P-generating system in vascular endothelial cells. Endothelial cells release SK constitutively and form S1P in the range of receptor stimulation. Levels of sphingosine but not ATP in the extracellular environment are rate-limiting. Treatment of endothelial cells with small interfering RNA for SK-1 transcript specifically inhibited SK export, and SK-1-transfected human embryonic kidney 293 cells exhibited enhanced release of SK-1. The export of SK-1 is constitutive and is inhibited by cytochalasin D and treatment at 4 degrees C but not by brefeldin A or nocodazole, suggesting that a nonclassical secretory pathway that requires the actin cytoskeleton dynamics is involved. Because S1P regulates angiogenesis and vascular maturation, we overexpressed SK-1 using an adenoviral vector in vivo in the Matrigel system of angiogenesis. Overexpression of SK-1 resulted in enhanced release of SK activity and induced angiogenesis and vascular maturation. These findings suggest that S1P is made in the extracellular milieu and that extracellular export of SK contributes to the action of S1P in the vascular system.
    Journal of Biological Chemistry 03/2002; 277(8):6667-75. DOI:10.1074/jbc.M102841200 · 4.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To identify airway pathologic abnormalities selectively associated with severe asthma, we examined 10 control subjects, 10 patients with intermittent asthma, 15 patients with mild-to-moderate persistent asthma, 15 patients with severe persistent asthma, and 10 patients with chronic obstructive pulmonary disease. Bronchial biopsies were assessed for epithelial integrity; subepithelial basement membrane (SBM) thickness; collagen type III deposition; eosinophil, neutrophil, and fibroblast numbers; mucous gland and airway smooth muscle (ASM) areas; SBM-ASM distance; ASM hypertrophy (increased cell size); and the expression of the contractile proteins alpha-actin, smooth muscle myosin heavy-chain isoforms, myosin light-chain kinase, and the phosphorylated form of the regulatory light chain of myosin. Neither mucosal eosinophilia nor neutrophilia, epithelial damage, or SBM thickness reflected asthma severity. In contrast, higher numbers of fibroblasts (p < 0.001), an increase in collagen type III deposition (p < 0.020), larger mucous gland (p < 0.040) and ASM (p < 0.001) areas, augmented ASM cell size (p < 0.001), and myosin light-chain kinase expression (p < 0.005) distinguished patients with severe persistent asthma from patients with milder disease or with chronic obstructive pulmonary disease. Stepwise multivariate regression analysis established that fibroblast numbers and ASM cell size were negatively associated with prebronchodilator and postbronchodilator FEV1 values in patients with asthma. We conclude that fibroblast accumulation and ASM hypertrophy in proximal airways are selective determinants of severe persistent asthma.
    American Journal of Respiratory and Critical Care Medicine 05/2003; 167(10):1360-8. DOI:10.1164/rccm.200209-1030OC · 11.99 Impact Factor